Naslov
Anti-IgE terapija astme i alergijskog rinitisa omalizumabom
(Anti-IgE therapy with omalizumab in asthma and allergic rhinitis)

Autori
Dodig, Slavica ; Richter, Darko ; Čepelak, Ivana ; Benko, Bojan

Izvornik
Acta Pharmaceutica (1330-0075) 55 (2005); 123 - 138

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, ostalo

Ključne riječi
astma; alergijski rinitis; terapija; anti-IgE; omalizumab
(asthma; allergic rhinitis; therapy; anti-IgE; omalizumab)

Sažetak
The pharmacology, efficacy, dosage, adverse events, and economics of anti IgE (omalizumab) are discussed. Omalizumab is generic name for the human/murine chimeric (recombinant humanized) monoclonal IgG antibody. Anti-IgE prevents IgE from attaching to effector cells, and thereby blunts IgE-mediated inflammatory responses. After subcutaneous administration it's absorption is slow, reaching peak concentration in serum after an average of 7-8 days. At recommended doses, serum free IgE levels decrease within 1 hour following the first dose and maintained between doses. Dose and dosing frequency is adjusted according to body mass and serum total IgE concentration before the start of treatment. Omalizumab administered subcutaneously is a effective treatment for add-on therapy in patients with poorly controlled, moderate-to-severe allergic asthma and allergic rhinitis (adults and adolescents >12 years). It reduce the requirement for inhaled corticosteroids while protecting against disease exacerbation. Omalizumab is well tolerated, but the safety profile required longer-term assessment in adults as well in children. The high cost limits its utility.

Izvorni jezik
Engleski

Znanstvena područja
Kemija, Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA